Who
Najat Khan
CEO and President
Company insider
Files Form 4 as: CEO and President, Recursion Pharmaceuticals.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Aug 2024
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $79K22,408 at $3.52 | filing |
| 8 Sep 2026filed 10 Sep 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $79K22,408 at $3.52 | filing |
| 17 Aug 2026filed 18 Aug 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $254K80,498 at $3.16 | filing |
| 17 Aug 2026filed 18 Aug 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $254K80,498 at $3.16 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $84K23,588 at $3.58 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $84K23,588 at $3.58 | filing |
| 15 May 2026filed 19 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $191K62,701 at $3.04 | filing |
| 15 May 2026filed 19 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $191K62,701 at $3.04 | filing |
| 9 Mar 2026filed 11 Mar 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K28,298 at $3.35 | filing |
| 9 Mar 2026filed 11 Mar 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K28,298 at $3.35 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $50K14,280 at $3.49 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $50K14,280 at $3.49 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,673,546 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,346 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $41K10,364 at $3.98 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,673,546 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —30,346 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $41K10,364 at $3.98 | filing |
| 22 Dec 2025filed 29 Dec 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $549K124,403 at $4.41 | filing |
| 17 Nov 2025filed 19 Nov 2025 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $73K17,584 at $4.14 | filing |
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Najat Khan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.